The Effect Of Lisinopril On Polycythemia
Start Date
7/1/2026
Completion Date
7/1/2029
Summary
The purpose of this study is to evaluate the effect of the (angiotensin-converting enzyme) ACE inhibitor lisinopril on hemoglobin, hematocrit, and erythropoietin levels in patients with secondary polycythemia due to high-oxygen-affinity hemoglobin variants, oxygen-sensing pathway mutations, or other unexplained and potentially irreversible forms of erythrocytosis. This study aims to determine whether ACE inhibition can effectively reduce excessive erythrocytosis by modulating erythropoietin production.
Detailed Description
Demonstrating that ACE inhibitor therapy with lisinopril lowers hemoglobin, hematocrit, and erythropoietin levels could introduce a novel therapeutic approach for the management of secondary polycythemia due to high-oxygen-affinity hemoglobin variants, oxygen-sensing pathway mutations, or other unexplained and potentially irreversible forms of erythrocytosis, potentially reducing reliance on repeated phlebotomies and lowering thrombotic risk.
Eligibility Criteria
Age Range: 18 years to 80 years
Interventions
Lisinopril Tablets
Conditions
Locations
Mayo Clinic
Rochester, Minnesota 55902
United States
St. Mary's Hospital
Rochester, Minnesota 55902
United States